Gene therapy for Glut1-deficient mouse using an adeno-associated virus vector with the human intrinsic GLUT1 promoter

被引:17
|
作者
Nakamura, Sachie [1 ]
Muramatsu, Shin-ichi [2 ,7 ]
Takino, Naomi [2 ]
Ito, Mika [2 ]
Jimbo, Eriko F. [1 ]
Shimazaki, Kuniko [3 ]
Onaka, Tatsushi [4 ]
Ohtsuki, Sumio [5 ]
Terasaki, Tetsuya [6 ]
Yamagata, Takanori [1 ]
Osaka, Hitoshi [1 ]
机构
[1] Jichi Med Univ, Dept Pediat, Shimotsuke, Tochigi, Japan
[2] Jichi Med Univ, Div Neurol, Shimotsuke, Tochigi, Japan
[3] Jichi Med Univ, Dept Neurosurg, Shimotsuke, Tochigi, Japan
[4] Jichi Med Univ, Dept Physiol, Div Brain & Neurophysiol, Shimotsuke, Tochigi, Japan
[5] Kumamoto Univ, Dept Pharmaceut Microbiol, Fac Life Sci, Kumamoto, Japan
[6] Tohoku Univ, Grad Sch Pharmaceut Sci, Div Membrane Transport & Drug Targeting, Sendai, Miyagi, Japan
[7] Univ Tokyo, Inst Med Sci, Ctr Gene & Cell Therapy, Tokyo, Japan
来源
JOURNAL OF GENE MEDICINE | 2018年 / 20卷 / 04期
基金
日本学术振兴会;
关键词
adeno-associated virus (AAV); gene therapy; glucose transporter 1 deficiency syndrome (GLUT1DS); GLUT1; SLC2A1; GLUCOSE-TRANSPORTER-1 DEFICIENCY SYNDROME; GLUCOSE-TRANSPORTER PROTEINS; NATIONWIDE SURVEY; KETOGENIC DIET; BRAIN; DELIVERY; MODEL; EXPRESSION; NEURONS; HYPEROSMOLARITY;
D O I
10.1002/jgm.3013
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
BackgroundWe generated an adeno-associated virus (AAV) vector in which the human SLC2A1 gene, encoding glucose transporter type 1 (GLUT1), was expressed under the human endogenous GLUT1 promoter (AAV-GLUT1). We examined whether AAV-GLUT1 administration could lead to functional improvement in GLUT1-deficient mice. MethodsWe extrapolated human endogenous GLUT1 promoter sequences from rat minimal Glut1 promoter sequences. We generated a tyrosine-mutant AAV9/3 vector in which human SLC2A1-myc-DDK was expressed under the human GLUT1 promoter (AAV-GLUT1). AAV-GLUT1 was administered to GLUT1-deficient mice (GLUT1(+/-) mice) via intracerebroventricular injection (1.85 x 10(10) vg/mouse or 6.5 x 10(10) vg/mouse). We analyzed exogenous GLUT1 mRNA and protein expression in the brain and other major organs. We also examined improvements of cerebral microvasculature, motor function using rota-rod and footprint tests, as well as blood and cerebrospinal fluid (CSF) glucose levels. Additionally, we confirmed exogenous GLUT1 protein distribution in the brain and other organs after intracardiac injection (7.8 x 10(11) vg/mouse). ResultsExogenous GLUT1 protein was strongly expressed in the cerebral cortex, hippocampus and thalamus. It was mainly expressed in endothelial cells, and partially expressed in neural cells and oligodendrocytes. Motor function and CSF glucose levels were significantly improved following intracerebroventricular injection. Exogenous GLUT1 expression was not detected in other organs after intracerebroventricular injection of AAV-GLUT1, whereas it was detected in the liver and muscle tissue after intracardiac injection. ConclusionsExogenous GLUT1 expression after AAV-GLUT1 injection approximated that of physiological human GLUT1 expression. Local central nervous system administration of AAV-GLUT1 improved CSF glucose levels and motor function of GLUT1-deficient mice and minimized off-target effects.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Gene Therapy for Glut1-Deficient Mouse Using AAV Vector with the Human Intrinsic Glut1 Promoter
    Nakamura, Sachie
    Osaka, Hitoshi
    Muramatsu, Shin-ichi
    Takino, Naomi
    Ito, Mika
    Jimbo, Eriko F.
    Shimazaki, Kuniko
    Onaka, Tatsushi
    Ohtsuki, Sumio
    Terasaki, Tetsuya
    Yamagata, Takanori
    MOLECULAR THERAPY, 2018, 26 (05) : 130 - 131
  • [2] Gene Therapy for Glut1 Deficiency Syndrome
    Monani, U. R.
    Tang, M.
    Yang, H.
    Li, H.
    Engelstad, K.
    Shetler, K.
    Gao, G.
    De Vivo, D. C.
    ANNALS OF NEUROLOGY, 2014, 76 : S176 - S176
  • [3] Gene therapy for phenylketonuria mouse model using pseudotyped adeno-associated virus vector
    Choi, Jin-Ok
    Park, Joo-Won
    Oh, Hyun-Jeong
    Seo, Kyung-In
    Park, Hae-Young
    Jung, Sung-Chul
    FASEB JOURNAL, 2007, 21 (06): : A1149 - A1149
  • [4] Adeno-associated virus as a delivery vector for gene therapy of human diseases
    Wang, Jiang-Hui
    Gessler, Dominic J.
    Zhan, Wei
    Gallagher, Thomas L.
    Gao, Guangping
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [5] Adeno-associated virus as a delivery vector for gene therapy of human diseases
    Jiang-Hui Wang
    Dominic J. Gessler
    Wei Zhan
    Thomas L. Gallagher
    Guangping Gao
    Signal Transduction and Targeted Therapy, 9
  • [6] Adeno-associated virus serotypes: Vector toolkit for human gene therapy
    Wu, Zhijian
    Asokan, Aravind
    Samulski, R. Jude
    MOLECULAR THERAPY, 2006, 14 (03) : 316 - 327
  • [7] Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
    Michael F. Naso
    Brian Tomkowicz
    William L. Perry
    William R. Strohl
    BioDrugs, 2017, 31 : 317 - 334
  • [8] Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
    Naso, Michael F.
    Tomkowicz, Brian
    Perry, William L., III
    Strohl, William R.
    BIODRUGS, 2017, 31 (04) : 317 - 334
  • [9] The adeno-associated virus vector for orthopaedic gene therapy
    Schwarz, EM
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2000, (379) : S31 - S39
  • [10] Phenotype analyses of a novel GLUT1 deficient syndrome model mouse
    Furuse, Tamio
    Wada, Yumiko
    Mizuma, Hiroshi
    Yamada, Ikuko
    Kushida, Tomoko
    Shibukawa, Yoko
    Masuya, Hiroshi
    Kaneda, Hideki
    Kobayashi, Kimio
    Miura, Ikuo
    Kaneko, Koichi
    Onoe, Hirotaka
    Wakana, Shigeharu
    NEUROSCIENCE RESEARCH, 2009, 65 : S252 - S252